ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates
Globe Newswire•16/11/2026•16:05 ET
0
Key Highlights
- ➤Rinzimetostat Himalayas-1 Phase 3 trial initiated in post-abiraterone mCRPC
- ➤Rinzimetostat landmark rPFS reached 59% at 8, 9, and 10 months post-abiraterone
- ➤Enozertinib produced 84% systemic and 70% CNS ORR in 1L EGFR atypical NSCLC
- ➤Redwood-1 Phase 3 trial planned for 1H 2027 in 1L EGFR atypical NSCLC
- ➤Cash and investments totaled $345.4 million, funding operations into 2H 2028
Expert Statements
Jacob M. Chacko, M.D., President and Chief Executive Officer of ORIC Pharmaceuticals
“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC”
Jacob M. Chacko, M.D., President and Chief Executive Officer of ORIC Pharmaceuticals
“With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer.”
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer
Provided updated rinzimetostat combination data in post-abiraterone mCRPC and in post-AR inhibitor mCRPC, consisting of landmark rPFS estimates in both populations that remain consistent with competitor PRC2 inhibitor, and reconfirming a highly differentiated safety profile
Get started
Create a free account to read the full story.
